Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study.
Yi-Ju LiaoTzu-Hung HsiaoChing-Heng LinChun-Sheng HsuYen-Lin ChangYu-Wei ChenChiann-Yi HsuYi Ming ChenMing-Fen WuPublished in: Pharmacogenomics and personalized medicine (2022)
In this hospital-wide cohort, 8.2% were clopidogrel users, of which 14.9% were CYP2C19 PMs. The result of this study does not support universal genotyping of CYP2C19 in all clopidogrel users to identify risks for stroke and AMI. CYP2C19 PMs are more likely to undergo multiple carotid interventions than non-PMs. Prospective studies to investigate the association of the CYP2C19 genotype and carotid interventions and outcomes are needed to validate our results.
Keyphrases
- acute coronary syndrome
- patients undergoing
- percutaneous coronary intervention
- randomized controlled trial
- physical activity
- healthcare
- acute myocardial infarction
- heart failure
- atrial fibrillation
- genome wide
- metabolic syndrome
- adipose tissue
- dna methylation
- insulin resistance
- weight loss
- climate change
- subarachnoid hemorrhage
- brain injury
- human health
- blood brain barrier
- adverse drug